NervGen Pharma Reports Financial Results with Increased R&D Spending

NervGen Pharma (NGEN) has released its latest financial results, showing a narrowing of diluted loss per share to C$0.06 compared to C$0.07 in the previous year. However, the company's total net loss expanded by 36% year-over-year, reaching C$6.4 million. The increase in losses is primarily driven by significant growth in operational spending. Research and development (R&D) expenses rose by 84% to C$7.9 million, while general and administrative (G&A) expenses surged by 154% to C$3.3 million, reflecting intensified investment in the company's clinical pipeline.

By https://seekingalpha.com/user/51785401/bio · Seeking Alpha ·

NervGen Pharma Reports Financial Results with Increased R&D Spending

Topics: earnings report net loss operating expenses R&D expenses

Read the full article at Seeking Alpha

More World news